{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:49:11Z","timestamp":1772855351526,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health","award":["ZIAAR041199"],"award-info":[{"award-number":["ZIAAR041199"]}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1136\/ard-2022-222658","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T17:58:00Z","timestamp":1659376680000},"page":"1576-1584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Peroxisome proliferator activated receptor-\u03b3 agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus"],"prefix":"10.1016","volume":"81","clinical-trial-number":[{"clinical-trial-number":"nct02338999","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4164-8837","authenticated-orcid":false,"given":"Sarfaraz","family":"Hasni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yenealem","family":"Temesgen-Oyelakin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Poncio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Naqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8255-3554","authenticated-orcid":false,"given":"Sarthak","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinghao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dillon","family":"Claybaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Dey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shajia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9729-4572","authenticated-orcid":false,"given":"Philip","family":"Carlucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2756-161X","authenticated-orcid":false,"given":"Monica","family":"Purmalek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zerai G","family":"Manna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Ochoa-Navas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinguo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amrita","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu Lee","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foo","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Koroleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmine","family":"Belkaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-3047","authenticated-orcid":false,"given":"John S","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Apps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald E","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9084-6736","authenticated-orcid":false,"given":"Massimo","family":"Gadina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5571-7266","authenticated-orcid":false,"given":"Martin P","family":"Playford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4939-5130","authenticated-orcid":false,"given":"Nehal N","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2968-0815","authenticated-orcid":false,"given":"Mariana J","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-222658_bib1","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa035471","article-title":"Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Roman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222658_bib2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","article-title":"Age-Specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study","volume":"145","author":"Manzi","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1136\/ard-2022-222658_bib3","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1002\/art.22924","article-title":"Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus","volume":"56","author":"Roman","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222658_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00002281-200309000-00001","article-title":"Update on vascular disease in systemic lupus erythematosus","volume":"15","author":"Kao","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard-2022-222658_bib5","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/rheumatology\/kei142","article-title":"\u2018Not only\u2026but also\u2019: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus","volume":"44","author":"Bruce","year":"2005","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222658_bib6","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99276","article-title":"Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus","volume":"3","author":"Carlucci","year":"2018","journal-title":"JCI Insight"},{"key":"10.1136\/ard-2022-222658_bib7","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1002\/art.34504","article-title":"Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis","volume":"64","author":"Thacker","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222658_bib8","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144918","article-title":"Bite of the wolf: innate immune responses propagate autoimmunity in lupus","volume":"131","author":"Gupta","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1136\/ard-2022-222658_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000332","article-title":"Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE","volume":"6","author":"Purmalek","year":"2019","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2022-222658_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai7616","article-title":"Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome","volume":"2","author":"Ghazarian","year":"2017","journal-title":"Sci Immunol"},{"key":"10.1136\/ard-2022-222658_bib11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/art.41518","article-title":"Modulation of cardiometabolic disease markers by type I interferon inhibition in systemic lupus erythematosus","volume":"73","author":"Casey","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222658_bib12","first-page":"389","article-title":"Effect of the metabolic syndrome on organ damage and mortality in patients with systemic lupus erythematosus: a longitudinal analysis","volume":"36","author":"Mok","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-222658_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2022-222658_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijcard.2012.09.190","article-title":"Efficacy and safety of statins in the prevention of atherosclerosis in patients with systemic lupus erythematosus\u2013a meta-analysis of randomized controlled trials","volume":"167","author":"Ye","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1136\/ard-2022-222658_bib15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard.2010.136762","article-title":"Lupus atherosclerosis prevention study (LAPS)","volume":"70","author":"Petri","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222658_bib16","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1080\/14656566.2020.1770227","article-title":"Management of cardiovascular disease in patients with systemic lupus erythematosus","volume":"21","author":"Piranavan","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"10.1136\/ard-2022-222658_bib17","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1177\/0961203311411347","article-title":"Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients","volume":"20","author":"Sazliyana","year":"2011","journal-title":"Lupus"},{"key":"10.1136\/ard-2022-222658_bib18","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.cardiores.2004.12.008","article-title":"Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock","volume":"65","author":"Abdelrahman","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1136\/ard-2022-222658_bib19","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4049\/jimmunol.182.1.340","article-title":"The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin","volume":"182","author":"Aprahamian","year":"2009","journal-title":"J Immunol"},{"key":"10.1136\/ard-2022-222658_bib20","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.4049\/jimmunol.0804341","article-title":"The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus","volume":"183","author":"Zhao","year":"2009","journal-title":"J Immunol"},{"key":"10.1136\/ard-2022-222658_bib21","doi-asserted-by":"crossref","first-page":"R1282","DOI":"10.1152\/ajpregu.90992.2008","article-title":"Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus","volume":"296","author":"Venegas-Pont","year":"2009","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1136\/ard-2022-222658_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000441","article-title":"The peroxisome proliferator activated receptor-\u03b3 pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis","volume":"2","author":"Marder","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1136\/ard-2022-222658_bib23","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/ar4290","article-title":"Peroxisome proliferator-activated receptor \u03b3 agonist effect on rheumatoid arthritis: a randomized controlled trial","volume":"15","author":"Ormseth","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222658_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222658_bib25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/bmj.305.6854.645-c","article-title":"Validating the SF-36","volume":"305","author":"Gompertz","year":"1992","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-222658_bib26","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-222658_bib27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/ard.2010.132068","article-title":"An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA","volume":"70","author":"Isenberg","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222658_bib28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12026-015-8712-7","article-title":"A pilot study to determine the optimal timing of the physician global assessment (PGA) in patients with systemic lupus erythematosus","volume":"63","author":"Aranow","year":"2015","journal-title":"Immunol Res"},{"key":"10.1136\/ard-2022-222658_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5551\/jat.32797","article-title":"The role of a novel arterial stiffness parameter, Cardio-Ankle vascular index (CAVI), as a surrogate marker for cardiovascular diseases","volume":"23","author":"Saiki","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"10.1136\/ard-2022-222658_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cca.2007.04.023","article-title":"Atherosclerosis is accelerated in patients with long-term well-controlled systemic lupus erythematosus (SLE)","volume":"385","author":"Sato","year":"2007","journal-title":"Clin Chim Acta"},{"key":"10.1136\/ard-2022-222658_bib31","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1097\/HJH.0000000000001437","article-title":"Reference values of cardio-ankle vascular index in a random sample of a white population","volume":"35","author":"Wohlfahrt","year":"2017","journal-title":"J Hypertens"},{"key":"10.1136\/ard-2022-222658_bib32","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1210\/clinem\/dgz252","article-title":"Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis","volume":"105","author":"Zhou","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1136\/ard-2022-222658_bib33","first-page":"50","article-title":"Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus","volume":"33","author":"El Magadmi","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-222658_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0961203311422096","article-title":"Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial","volume":"21","author":"Ju\u00e1rez-Rojas","year":"2012","journal-title":"Lupus"},{"key":"10.1136\/ard-2022-222658_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1136\/ard-2022-222658_bib36","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/dme.12144","article-title":"Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies","volume":"30","author":"Ferwana","year":"2013","journal-title":"Diabet Med"},{"key":"10.1136\/ard-2022-222658_bib37","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.2174\/1381612825666190920123129","article-title":"Pioglitazone therapy decreases bone mass density and increases fat mass: a meta-analysis","volume":"25","author":"Zuo","year":"2019","journal-title":"Curr Pharm Des"},{"key":"10.1136\/ard-2022-222658_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1475-2840-8-15","article-title":"Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes","volume":"8","author":"Dorkhan","year":"2009","journal-title":"Cardiovasc Diabetol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724183987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724183987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-222658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:42:10Z","timestamp":1739522530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724183987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0003496724183987"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-222658","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peroxisome proliferator activated receptor-\u03b3 agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-222658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 \u00a9 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}